Leerink Partners analyst Thomas Smith has maintained their neutral stance on KYMR stock, giving a Hold rating yesterday.
Geoff Meacham has given his Hold rating due to a combination of factors pertaining to Kymera Therapeutics’ recent R&D updates and their long-term financial prospects. The Immunology R&D Day showcased two promising new candidates, KT-621 and KT-294, with strong preclinical data, including effective target degradation without impacting non-target proteins. Moreover, the company has solid plans to initiate Phase 1 trials for these candidates within the next two years. Despite these positive developments and the successful funding efforts that extended the company’s financial runway, Meacham remains cautious, as the new programs are still in early development stages without a defined value in the current financial assessment.
Furthermore, the ongoing clinical development of KT-474 has been reaffirmed with enrollment completion expected in 2024 and top-line data anticipated by the first half of 2025. While there are promising signs for Kymera’s expanding immunology pipeline, Meacham has opted for a conservative valuation, attributing approximately $200 million in risk-adjusted net present value to the company’s early pipeline candidates. The market’s reaction to the R&D event was notably positive, yet the Hold rating reflects a watchful approach pending more definitive clinical data that could potentially alter investor perception and meaningfully impact share value in the longer term.
In another report released yesterday, Morgan Stanley also maintained a Hold rating on the stock with a $33.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KYMR in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Kymera Therapeutics (KYMR) Company Description:
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera’s Pegasus targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade the intractable of proteins, and advance new treatment options for patients.
Read More on KYMR:
- Kymera Therapeutics 2.25M share Spot Secondary priced at $25.25
- Kymera Therapeutics Announces Pricing of $275 Million Public Offering
- Kymera Therapeutics $250M Spot Secondary; re-offered at $25.25
- Kymera Therapeutics announces $250M common stock offering
- Kymera Therapeutics Announces Proposed Public Offering
